A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
This study is testing an investigational drug called CBL0137 to see how well it works and what side effects it might have in children and young adults. The drug works by blocking signals inside cancer cells, which may help stop them from growing and cause them to die.
This trial is open to patients between 1 and 21 years old who have solid tumors, brain or spinal cord tumors, or lymphoma that has returned or stopped responding to standard treatments. Participants must also meet specific health guidelines and agree to use birth control if they are able to have children.
Participants will receive the study drug CBL0137 and undergo regular medical tests, which include blood draws, tissue or bone marrow samples, and heart ultrasounds to monitor their health. The study team will carefully check how the body responds to the treatment and manage any side effects.
The study is currently recruiting patients at medical centers in locations including Alabama, Arizona, and California. You can talk to your care team to see if one of these locations is convenient for you.
- 1Testing a new drug called CBL0137 for young patients with hard-to-treat cancers
- 2Open to individuals ages 1 to 21 with solid tumors, brain tumors, or lymphoma
- 3Involves regular health checks like blood tests and heart scans alongside treatment
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.